Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
6.36
+0.03 (0.47%)
Dec 24, 2025, 1:00 PM EST - Market closed
Company Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.
The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus.
It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Kezar Life Sciences, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Christopher Kirk |
Contact Details
Address: 4000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 822 5600 |
| Website | kezarlifesciences.com |
Stock Details
| Ticker Symbol | KZR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645666 |
| CUSIP Number | 49372L100 |
| ISIN Number | US49372L2097 |
| Employer ID | 47-3366145 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, Chief Executive Officer and Director |
| John Franklin Fowler | Co-Founder and Director |
| Marc L. Belsky CPA | Chief Financial Officer and Secretary |
| Mark Schiller | Chief Operations Officer |
| Dr. Jack Taunton Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 7, 2025 | 8-K | Current Report |
| Oct 22, 2025 | 8-K | Current Report |
| Oct 16, 2025 | 8-K | Current Report |
| Sep 8, 2025 | SCHEDULE 13G | Filing |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 8-K | Current Report |